Arizona State Retirement System Increases Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Arizona State Retirement System increased its holdings in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 4.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,497 shares of the company’s stock after purchasing an additional 486 shares during the period. Arizona State Retirement System’s holdings in Omnicell were worth $630,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Omnicell by 0.3% in the first quarter. Vanguard Group Inc. now owns 4,752,906 shares of the company’s stock valued at $615,453,000 after purchasing an additional 12,413 shares during the period. Macquarie Group Ltd. grew its position in shares of Omnicell by 12.5% in the second quarter. Macquarie Group Ltd. now owns 1,218,279 shares of the company’s stock valued at $138,579,000 after purchasing an additional 135,360 shares during the period. Clearbridge Investments LLC grew its position in Omnicell by 8.9% during the first quarter. Clearbridge Investments LLC now owns 1,136,664 shares of the company’s stock valued at $147,187,000 after acquiring an additional 92,567 shares during the period. Lazard Asset Management LLC grew its position in Omnicell by 24.1% during the third quarter. Lazard Asset Management LLC now owns 1,097,358 shares of the company’s stock valued at $95,502,000 after acquiring an additional 212,817 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Omnicell by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after acquiring an additional 4,839 shares during the period.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $72.24 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.06 and a quick ratio of 1.75. Omnicell, Inc. has a 1-year low of $46.11 and a 1-year high of $125.17. The business has a 50-day moving average of $60.03 and a 200-day moving average of $55.53. The company has a market capitalization of $3.26 billion, a price-to-earnings ratio of -180.60, a PEG ratio of 10.28 and a beta of 0.90.

Omnicell (NASDAQ:OMCL – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.20. Omnicell had a positive return on equity of 5.38% and a negative net margin of 1.39%. The business had revenue of $297.67 million for the quarter, compared to analysts’ expectations of $286.32 million. On average, equities analysts anticipate that Omnicell, Inc. will post 0.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Joanne B. Bauer sold 13,115 shares of the business’s stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of $54.24, for a total value of $711,357.60. Following the transaction, the director now owns 28,096 shares in the company, valued at $1,523,927.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 2.61% of the company’s stock.

Analyst Upgrades and Downgrades

OMCL has been the subject of a number of research reports. TheStreet downgraded Omnicell from a “c” rating to a “d+” rating in a research report on Tuesday, February 28th. SVB Leerink reissued a “market perform” rating on shares of Omnicell in a research report on Friday, January 27th. Benchmark raised Omnicell from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research report on Monday, February 27th. StockNews.com initiated coverage on Omnicell in a research report on Thursday. They set a “hold” rating for the company. Finally, KeyCorp boosted their price target on Omnicell from $65.00 to $70.00 in a research report on Wednesday, May 3rd. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $72.22.

Omnicell Profile

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.